clinical trial · NCT00626795
Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
LEO Pharma·phase2·completed·n = 773
ImpetigoSecondarily Infected Traumatic LesionsTD1414 2% creamTD1414 2% creamBactroban® (mupirocin) 2% cream
brief summary
An international, multi-centre, prospective three arm parallel-group, phase II proof of concept study comparing the efficacy and safety of two dosage regimens (BID 7 days and TID 7 days) of TD1414 2% cream and one dosage regimen (BID 7 days) of Bactroban® (mupirocin) 2% cream in adults and children down to 2 years of age with impetigo or SITL. Furthermore an evaluation of the pharmacokinetics of TD1414 2% cream TID for 7 days will be performed. A total of 664 patients will be enrolled in a stepwise manner according to age groups starting with the oldest age group.
started
Feb 1, 2008
primary completion
Mar 1, 2009
completion
Jun 1, 2009
last updated
Mar 12, 2025
official title
Efficacy, Safety and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol